Jupiter Topco LLC Takes Position in ICU Medical, Inc. $ICUI

Jupiter Topco LLC purchased a new stake in ICU Medical, Inc. (NASDAQ:ICUI) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,781,620 shares of the medical instruments supplier’s stock, valued at approximately $407,786,000. Jupiter Topco LLC owned about 11.13% of ICU Medical as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ICUI. Norges Bank acquired a new position in shares of ICU Medical during the fourth quarter worth approximately $58,083,000. Kirr Marbach & Co. LLC IN increased its holdings in shares of ICU Medical by 18.4% in the first quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock valued at $5,702,000 after purchasing an additional 6,863 shares in the last quarter. F m Investments LLC increased its holdings in shares of ICU Medical by 33.3% in the fourth quarter. F m Investments LLC now owns 46,519 shares of the medical instruments supplier’s stock valued at $6,637,000 after purchasing an additional 11,608 shares in the last quarter. Thrivent Financial for Lutherans raised its position in ICU Medical by 1,604.0% in the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after purchasing an additional 285,648 shares during the last quarter. Finally, Reinhart Partners LLC. bought a new position in ICU Medical in the 2nd quarter worth approximately $46,148,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Buying and Selling

In related news, insider Ben Sousa sold 2,250 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total value of $401,220.00. Following the completion of the sale, the insider owned 3,076 shares in the company, valued at approximately $548,512.32. This represents a 42.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Christian B. Voigtlander sold 8,929 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $182.93, for a total value of $1,633,381.97. Following the completion of the transaction, the chief operating officer directly owned 37,377 shares in the company, valued at $6,837,374.61. The trade was a 19.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,974 shares of company stock valued at $3,085,844 in the last three months. 2.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ICUI. Raymond James Financial reiterated a “strong-buy” rating and issued a $200.00 price objective on shares of ICU Medical in a research report on Friday, August 7th. BTIG Research boosted their target price on ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. KeyCorp upped their price target on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Needham & Company LLC raised their price target on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Wall Street Zen upgraded ICU Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $192.80.

ICU Medical Price Performance

Shares of ICUI stock opened at $182.24 on Wednesday. ICU Medical, Inc. has a 52-week low of $112.50 and a 52-week high of $192.85. The stock has a market cap of $4.55 billion, a PE ratio of 154.44, a PEG ratio of 2.31 and a beta of 0.74. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43. The firm’s 50 day moving average price is $162.42 and its two-hundred day moving average price is $143.53.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $1.91 by $0.46. The company had revenue of $547.88 million during the quarter, compared to analysts’ expectations of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, analysts forecast that ICU Medical, Inc. will post 7.19 EPS for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.